{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-066327","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.725128+00:00","generated_at":"2026-05-31T10:44:50.376395+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aldeyra achieves primary endpoint in Phase 3 dry eye trial of reproxalap; NDA resubmission planned 2024","bullets":["Primary endpoint of ocular discomfort met (p=0.004) vs vehicle in 132-patient Phase 3 dry eye chamber trial.","NDA resubmission for reproxalap anticipated in 2024; FDA review period expected ~6 months.","Reproxalap studied in over 2,500 patients; no safety signals; mild transient instillation site discomfort most common AE.","Option agreement with AbbVie includes $100M upfront if exercised, plus up to $300M milestones and profit/loss share."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-066327","json":"https://secwatch.observer/filing/0001213900-24-066327.json","markdown":"https://secwatch.observer/filing/0001213900-24-066327.md","text":"https://secwatch.observer/filing/0001213900-24-066327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/0001213900-24-066327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/ea0210840-8k_aldeyra.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:44:50.376395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}